{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+3&page=2",
    "query": {
      "intervention": "Arm 3",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+3&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T13:40:01.322Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06692933",
      "title": "Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Interaction"
      ],
      "interventions": [
        {
          "name": "Cannabidiol in the form of hemp",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "21 Years to 64 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-06-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06692933"
    },
    {
      "nct_id": "NCT05756647",
      "title": "Mandibular Advancement vs Home Treatment for Primary Snoring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Snoring"
      ],
      "interventions": [
        {
          "name": "Interventional Arm",
          "type": "DEVICE"
        },
        {
          "name": "Conservative treatment Arm",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-11-07",
      "completion_date": "2023-07-03",
      "has_results": true,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756647"
    },
    {
      "nct_id": "NCT02930226",
      "title": "Ascending Doses of Autologous FDP vs FFP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Freeze Dried Plasma in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Autologous Freeze Dried Plasma (FDP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fresh Frozen Plasma (FFP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-02-13",
      "completion_date": "2018-08-02",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930226"
    },
    {
      "nct_id": "NCT04191135",
      "title": "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2019-12-19",
      "completion_date": "2025-11-26",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 25,
      "location_summary": "Monterey, California • San Francisco, California • Santa Monica, California + 20 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191135"
    },
    {
      "nct_id": "NCT03329508",
      "title": "A Phase 3 Study With P2B001 in Subjects With Early Parkinson's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Early Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "P2B001 0.6/0.75 mg",
          "type": "DRUG"
        },
        {
          "name": "Rasagiline 0.75 mg",
          "type": "DRUG"
        },
        {
          "name": "Pramipexole 0.6 mg",
          "type": "DRUG"
        },
        {
          "name": "Marketed Pramipexole ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharma Two B Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 544,
      "start_date": "2018-01-19",
      "completion_date": "2021-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 45,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329508"
    },
    {
      "nct_id": "NCT00912340",
      "title": "Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2009-05",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2018-12-05",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Madison, Wisconsin",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912340"
    },
    {
      "nct_id": "NCT07218289",
      "title": "Green Light for Post-Operative Wellness",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Surgery"
      ],
      "interventions": [
        {
          "name": "Bright Green Light Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Dim White Light Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rebecca E Kotcher, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-01-14",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218289"
    },
    {
      "nct_id": "NCT02145091",
      "title": "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Moderately-high dose of psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Moderately-low dose of psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Very-low dose of psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-05",
      "completion_date": "2019-12-26",
      "has_results": false,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145091"
    },
    {
      "nct_id": "NCT03152318",
      "title": "A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma of Brain",
        "Astrocytoma",
        "Malignant Astrocytoma",
        "Oligodendroglioma",
        "Anaplastic Oligodendroglioma of Brain (Diagnosis)",
        "Mixed Oligo-Astrocytoma",
        "Ependymoma",
        "Ganglioglioma",
        "Pylocytic/Pylomyxoid Astrocytoma",
        "Brain Tumor",
        "Glioma",
        "Brain Cancer",
        "Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "rQNestin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-18",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152318"
    },
    {
      "nct_id": "NCT05077904",
      "title": "A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stereotypical Prolonged Seizures"
      ],
      "interventions": [
        {
          "name": "Staccato alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2021-12-07",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-15T13:40:01.322Z",
      "location_count": 66,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05077904"
    }
  ]
}